港股异动 | 晶泰控股(02228)涨超10% 预计上半年收益同比激增近4倍 AI制药商业化落地加速

Core Viewpoint - Jingtai Holdings (02228) has experienced a significant stock increase of over 10% following the announcement of a positive earnings forecast, indicating strong growth potential driven by its collaboration in AI-driven drug discovery [1][2] Financial Performance - The company anticipates a consolidated revenue of no less than RMB 500 million for the period ending mid-2025, representing an increase of at least approximately 387% year-on-year [1] - Net profit is expected to be no less than RMB 50 million, with adjusted net profit projected to be no less than RMB 120 million, marking the company's first half-year profitability [1] Strategic Partnerships - The financial improvement is primarily attributed to the collaboration with DoveTree Medicines LLC and its affiliates, leveraging an end-to-end AI drug discovery platform and integrated "AI + robotics" technology [1] - The partnership has resulted in a significant revenue boost, with an initial payment of USD 51 million recognized as revenue for the mid-2025 period, contributing substantially to the company's earnings during the reporting period [1] Market Position and Growth Potential - Dongwu Securities highlights the company as a rare global player in AI for Science, considering the collaboration a milestone event [2] - The initial payment amount exceeded expectations, validating the value of Jingtai Holdings' AI and robotics technology in drug discovery, and establishing a solid foundation for future commercial orders [2] - The company's client base spans various sectors, including new materials, energy, and chemicals, further expanding its growth potential [2]